share_log

睿智医药(300149.SZ):公司具备针对糖尿病药物的包括大分子、小分子药物发现、药理药效、药代药动等方面的研发能力

Smart Medicine (300149.SZ): The company has research and development capabilities for diabetes drugs, including macromolecule and small molecule drug discovery, pharmacological efficacy, and pharmacokinetics

Gelonghui Finance ·  May 9 04:24

On May 9, Ge Longhui Pharmaceutical (300149.SZ) said on the investor interactive platform that the company belongs to the pharmaceutical R&D and production service (CRO/CDMO) industry and provides drug discovery, development and production services to global pharmaceutical companies, biotechnology companies and research institutes. The company has research and development capabilities for diabetes drugs, including macromolecular and small-molecule drug discovery, pharmacological efficacy, pharmacokinetics, etc., especially relevant target tests and animal models for type 1 and type 2 diabetes. The company has experience in providing related R&D services to customers in diabetes drug development.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment